What we do Torrent Pharmaceuticals is a leading Indian pharma company specializing in chronic therapies like cardiovascular, CNS, diabetes, and gastro-intestinal segments with global presence. |
Founded in 1,959 |
Market share Ranks 7th in India pharmaceutical market with strong presence across USA, Germany, Brazil, and emerging markets. |
Problem solved Addresses chronic and sub-chronic disease management through innovative niche pharmaceutical products and patient-centric therapies. |
Top clients or who we serve Serves doctors, hospitals, and patients with branded generics and generic medicines across B2B and B2C markets globally. |
Key management Executive Chairman Samir Mehta leads with a governance team supported by professional management and board expertise. |
Our journey and innovations Founded in 1959, public since 1972, expanded internationally through acquisitions and new product launches, pioneering in insulin manufacturing and oncology. |
Where we operate Operations span India, USA, Germany, Brazil, Mexico, Philippines, Japan, and other emerging markets across 40+ countries. |
Top products or what we offer Offers branded and generic pharmaceutical products in cardiovascular, CNS, vitamins, diabetes, gastro-intestinal, oncology, dermatology, and consumer health segments. |
Top brands Vorxarr (Saroglitazar), Kabvie (Vonoprazan), Shelcal Pro Adult Gummies, key cardiology and CNS drugs drive substantial revenues. |
Raw materials needed Active Pharmaceutical Ingredients (APIs), excipients, specialized chemicals for formulations and biologics development. |
Raw materials supplier Suppliers include domestic and international API manufacturers, often regulated to ensure quality and compliance. |
Recurring vs cyclical contribution Branded pharmaceutical sales contribute recurring revenues while generic product launches induce cyclical peaks. |
Our industry position Market leader in India's chronic therapy segments, top Indian pharma in Brazil, number five in German generics market. |
Financial highlights FY25 consolidated revenue Rs.11,516 crore with 7% growth; net profit Rs.1,911 crore with 15% growth; EBITDA margin improved to 32.3%. |
Geographical revenue split India 59%, Germany 10%, Brazil 9.6%, USA 9.5%, Other markets 12% of revenue in FY25. |
Order book Active product pipeline with new launches in oncology, biosimilars, and diabetes therapies supporting future growth. |
Whats driving growth Growth driven by branded business expansion, in-licensing, new product launches, increased field force, and strategic acquisitions like Curatio. |
Our future plans Focus on oncology, biosimilars, expanding consumer health, doubling field force, and international market penetration with new manufacturing. |
Our green promise Commitment to reducing carbon footprint via solar energy, waste management, and water conservation achieving significant emission cuts. |
Our people and values Strong employee base of 16,107 focused on diversity, health, safety, continuous learning, and ethical business culture. |
Key challenges ahead Competitive pricing pressures in generics, regulatory compliance in multiple geographies, and currency fluctuations. |
Interesting facts First Indian pharma with dedicated insulin manufacturing; launched first oncology drug in US; operates a NABH certified children’s hospital. |
Risks and strategy Mitigates regulatory, market, and operational risks through diversification, innovation, and robust risk management policies. |
